Kynam Capital Management, LP
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Kynam Capital Management, LP reported 31 stock positions worth $928.8 million. Its top holding was Celldex Therapeutics (CLDX) at 13.4% of the portfolio, followed by Vaxcyte (PCVX, 10.8%) and Vera Therapeutics (VERA, 8.7%). Compared with Q1 2025, it opened 2 new positions, sold out of 2, added to 4 and reduced 22. The biggest buy was Vera Therapeutics (VERA, shares +43%) and the biggest sale an exit from Natera (NTRA).
- Most Recent 13F
- Q2 2026
- Location
- PRINCETON, NJ
- CIK
- 0001907884
- Portfolio Value
- $928.8M (Q2 2025)
- SEC Filing
- 0001085146-25-005132 ↗ filed Aug 14, 2025
Holdings Value
Holdings 31 stocks · $928.8M
| CLDX Celldex Therapeutics Inc. | 13.37% | 6,100,729 | $124.1M | Reduce -6.1% |
| PCVX Vaxcyte Inc. | 10.75% | 3,071,588 | $99.9M | Reduce -4.0% |
| VERA Vera Therapeutics Inc. | 8.69% | 3,426,887 | $80.7M | Add +42.8% |
| SNDX Syndax Pharmaceuticals Inc. | 8.59% | 8,520,000 | $79.8M | No change |
| BCRX Biocryst Pharmaceuticals Inc. | 8.16% | 8,463,742 | $75.8M | Reduce -5.2% |
| CGON CG Oncology Inc. | 6.88% | 2,457,667 | $63.9M | Reduce -5.9% |
| VRDN Viridian Therapeutics Inc. | 6.66% | 4,427,927 | $61.9M | Reduce -5.8% |
| COGT Cogent Biosciences Inc. | 6.56% | 8,492,557 | $61.0M | Reduce -6.7% |
| BEAM Beam Therapeutics Inc. | 4.43% | 2,417,647 | $41.1M | Reduce -4.0% |
| IMCR Immunocore Holdings PLC-ADR | 3.30% | 976,267 | $30.6M | Reduce -42.4% |
| WVE Wave Life Sciences Ltd. | 3.19% | 4,560,053 | $29.6M | Reduce -6.9% |
| TVTX Travere Therapeutics Inc. | 2.46% | 1,540,691 | $22.8M | Reduce -14.5% |
| TYRA Tyra Biosciences Inc. | 2.40% | 2,329,998 | $22.3M | Reduce -3.2% |
| DVAX Dynavax Technologies Corp. | 2.29% | 2,145,319 | $21.3M | Reduce -18.1% |
| ENGN Engene Holdings Inc. | 1.96% | 4,994,090 | $18.2M | No change |
| CGEM Cullinan Therapeutics Inc. | 1.70% | 2,095,998 | $15.8M | Reduce -10.4% |
| NRIX Nurix Therapeutics Inc. | 1.44% | 1,173,605 | $13.4M | Add +46.7% |
| RLAY Relay Therapeutics Inc. | 1.08% | 2,887,014 | $10.0M | Reduce -5.8% |
| AMRN Amarin Corp. PLC -ADR | 1.01% | 576,111 | $9.3M | Reduce -7.2% |
| URGN Urogen Pharma Ltd. | 0.97% | 656,573 | $9.0M | Add +2526.3% |
| CTMX Cytomx Therapeutics Inc. | 0.53% | 2,154,413 | $4.9M | New |
| GERN Geron Corp. | 0.52% | 3,456,318 | $4.9M | Reduce -5.5% |
| IRWD Ironwood Pharmaceuticals Inc. | 0.42% | 5,466,825 | $3.9M | Reduce -6.1% |
| CRBU Caribou Biosciences Inc. | 0.42% | 3,067,774 | $3.9M | Reduce -6.2% |
| STRO Sutro Biopharma Inc. Com SHS | 0.39% | 5,088,099 | $3.6M | Reduce -6.5% |
| DSGN Design Therapeutics Inc. | 0.37% | 1,029,579 | $3.5M | Add +13.9% |
| PRQR Proqr Therapeutics NV | 0.36% | 1,649,462 | $3.4M | Reduce -5.8% |
| EWTX Edgewise Therapeutics Inc. | 0.36% | 253,979 | $3.3M | New |
| BNR Burning Rock Biotech Ltd.-ADR | 0.34% | 994,883 | $3.1M | No change |
| LQDA Liquidia Corp. | 0.27% | 200,047 | $2.5M | Reduce -68.4% |
| CLYM Climb Bio Inc. | 0.14% | 1,028,341 | $1.3M | Reduce -1.8% |
Portfolio Sells Q1 2025 → Q2 2025
| NTRA Natera Inc. | Sold out | 0.00% | −14.13 |
| LEGN Legend Biotech Corp.-ADR | Sold out | 0.00% | −1.77 |
| IMCR Immunocore Holdings PLC-ADR | Reduce -42.4% | 3.30% | −1.01 |
| DVAX Dynavax Technologies Corp. | Reduce -18.1% | 2.29% | −0.62 |
| LQDA Liquidia Corp. | Reduce -68.4% | 0.27% | −0.53 |
| IRWD Ironwood Pharmaceuticals Inc. | Reduce -6.1% | 0.42% | −0.31 |
| TVTX Travere Therapeutics Inc. | Reduce -14.5% | 2.46% | −0.31 |
| WVE Wave Life Sciences Ltd. | Reduce -6.9% | 3.19% | −0.20 |
| GERN Geron Corp. | Reduce -5.5% | 0.52% | +0.03 |
| CLYM Climb Bio Inc. | Reduce -1.8% | 0.14% | +0.03 |
| STRO Sutro Biopharma Inc. Com SHS | Reduce -6.5% | 0.39% | +0.09 |
| CRBU Caribou Biosciences Inc. | Reduce -6.2% | 0.42% | +0.16 |
| PRQR Proqr Therapeutics NV | Reduce -5.8% | 0.36% | +0.16 |
| CGEM Cullinan Therapeutics Inc. | Reduce -10.4% | 1.70% | +0.18 |
| BEAM Beam Therapeutics Inc. | Reduce -4.0% | 4.43% | +0.22 |
| RLAY Relay Therapeutics Inc. | Reduce -5.8% | 1.08% | +0.39 |
| PCVX Vaxcyte Inc. | Reduce -4.0% | 10.75% | +0.41 |
| TYRA Tyra Biosciences Inc. | Reduce -3.2% | 2.40% | +0.49 |
| AMRN Amarin Corp. PLC -ADR | Reduce -7.2% | 1.01% | +0.53 |
| VRDN Viridian Therapeutics Inc. | Reduce -5.8% | 6.66% | +1.24 |
| CGON CG Oncology Inc. | Reduce -5.9% | 6.88% | +1.41 |
| COGT Cogent Biosciences Inc. | Reduce -6.7% | 6.56% | +1.90 |
| BCRX Biocryst Pharmaceuticals Inc. | Reduce -5.2% | 8.16% | +2.43 |
| CLDX Celldex Therapeutics Inc. | Reduce -6.1% | 13.37% | +3.27 |
Portfolio Buys Q1 2025 → Q2 2025
Options Activity Q1 2025 → Q2 2025
| SLNO Soleno Therapeutics Inc. | call | Sold out | 302,500 | $21.6Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 32 | $1.8B | CLDX, SNDX, PCVX, COGT, VERA |
| Q1 2026 | 36 | $1.6B | SNDX, CLDX, PCVX, COGT, VERA |
| Q4 2025 | 35 | $1.5B | COGT, VERA, SNDX, CLDX, PCVX |
| Q3 2025 | 35 | $1.3B | CLDX, SNDX, VERA, COGT, PCVX |
| Q2 2025 | 31 | $928.8M | CLDX, PCVX, VERA, SNDX, BCRX |
| Q1 2025 | 31 | $1.2B | NTRA, PCVX, CLDX, SNDX, BCRX |
| Q4 2024 | 29 | $1.5B | NTRA, PCVX, CLDX, SNDX, DVAX |
| Q3 2024 | 24 | $1.3B | NTRA, PCVX, CLDX, SNDX, COGT |
| Q2 2024 | 22 | $955.2M | NTRA, CLDX, SNDX, DVAX, COGT |
| Q1 2024 | 21 | $898.9M | NTRA, SNDX, CLDX, VERA, COGT |